Key Drivers
- Margin Expansion
- Cash Generation
- Leverage Improvement
AIAI Summary
LQDA has moved from a survival biotech to a cash-generative commercial story with a much stronger balance sheet, but the investment now hinges almost entirely on sustaining YUTREPIA's launch because the United Therapeutics patent dispute could quickly disrupt the core revenue stream and erase the rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Cash Generation
- •Leverage Improvement
LQDA delivered a sharp quarterly turnaround with strong gross margins, solid free cash flow, and improved leverage, but full-year losses, a large deficit, and a rich valuation still make it highly execution-sensitive.
Price Behavior
Key Price Behavior Insights:
- •Breakout momentum
- •Higher-highs trend
- •Stretched extension
Over the last month, LQDA surged in a strong bullish breakout from $39.47 to $56.93, holding new support at $53.13 and $42.30 while approaching $59.30 resistance.
Sharp breakout and surge on 2026-05-11 suggest an overextended move with pullback risk
Sentiment & News
Key News Insights:
- •Earnings Beat
- •YUTREPIA Growth
- •Valuation Risk
Liquidia's strong Q1 beat, rising YUTREPIA sales, and sustained profitability have lifted sentiment and analyst forecasts, though valuation and competition risks remain.
The news is broadly positive for LQDA, with execution and product momentum supporting the shares, but upside may be moderated by launch competition and a rich valuation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings